Meeting
2019 Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
Authors
Lewis Thomas
Cleveland Clinic Foundation, Cleveland, OH
Lewis Thomas , Ryan Steinberg , Kenneth Gerard Nepple , Michael A. O'Donnell
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Prostate Cancer,Penile, Urethral, Testicular, and Adrenal Cancers
Sub Track
Urothelial Carcinoma
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr 469)
DOI
10.1200/JCO.2019.37.7_suppl.469
Abstract #
469
Poster Bd #
K18
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Intravesical gemcitabine and docetaxel in the treatment of BCG-naïve non–muscle invasive urothelial carcinoma of the bladder: Updates from a phase 2 trial.
First Author: Sunil H. Patel
Poster
2022 ASCO Genitourinary Cancers Symposium
Long-term follow-up of intravesical gemcitabine and docetaxel as rescue therapy for nonmuscle-invasive bladder cancer.
First Author: Phani T. Chevuru
Poster
2022 ASCO Genitourinary Cancers Symposium
Sequential intravesical gemcitabine and docetaxel for BCG-naïve high-risk nonmuscle-invasive bladder cancer.
First Author: Ian Mitchell McElree
Poster
2023 ASCO Annual Meeting
A phase I dose-escalation clinical trial with PLZ4-coated paclitaxel-loaded micelles (PPM) in patients with recurrent or refractory non-myoinvasive bladder cancer.
First Author: Hizra Farrukh